# EDGAR Filing Document

**Accession Number:** 0001822791
**File Stem:** 0001437749-25-034621
**Filing Date:** 2025-11
**Character Count:** 18655
**Document Hash:** 6681193f49323418fd1a02a65bbbb7ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-034621.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001437749-25-034621

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251113

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clene Inc.
- **CENTRAL INDEX KEY:** 0001822791
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852828339
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39834
- **FILM NUMBER:** 251475507

**BUSINESS ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121
- **BUSINESS PHONE:** 801-676-9695

**MAIL ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chelsea Worldwide Inc.
- **DATE OF NAME CHANGE:** 20200827

?xml version='1.0' encoding='ASCII'? clnn20250821_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM**8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)** 

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**November 13, 2025**

------

**CLENE INC.**

(Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39834** | **85-2828339** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) |  | Identification No.) |
| **6550 South Millrock Drive, Suite G50**<br> **Salt Lake City**,**Utah** |  | **84121** |
| (Address of principal executive offices) |  | (Zip Code) |

---

**(**801**)**676-9695**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report.)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value | CLNN | The Nasdaq Capital Market |
| Warrants, to acquire one-fortieth of one share of Common Stock for $230.00 per share | CLNNW | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On November 13, 2025, Clene Inc. (the "Company") issued a press release announcing its third quarter 2025 financial results and recent operating highlights for its quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **by Exhibit Description** |
| 99.1 | [Press Release, dated November 13, 2025, announcing the Company's third quarter 2025 financial results and recent operating highlights.](ex_855915.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | CLENE INC. | CLENE INC. |
| Date: November 13, 2025 | By: | /s/ Robert Etherington |
|  |  | Robert Etherington |
|  |  | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**CLENE REPORTS Third QUARTER 2025 FINANCIAL RESULTS**

**AND RECENT OPERATING HIGHLIGHTS**

● *As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly* 

● *The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analyses* 

● *The Company plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathway* 

● *The Company expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026* 

● *The FDA and Clene participated in a Type B end of Phase 2 meeting in the third quarter of 2025 to discuss the Company's MS clinical development program and ongoing plans for MS development of CNM-Au8* 

● *Cash and cash equivalents of $7.9 million as of September 30, 2025* 

● *Cash runway extended into the second quarter of 2026, including $1.2 million additionally raised following the third quarter close* 

**SALT LAKE CITY, November 13, 2025** -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its third quarter 2025 financial results and provided recent updates on its CNM-Au8 programs.

"The three potential biomarker paths that could be leveraged to increase the persuasiveness of our ALS data, as outlined by the FDA, include: a) the NfL analysis of our ongoing NIH-sponsored Expanded Access Program (EAP); b) additional ALS disease-specific biomarker changes (in addition to NfL) from the HEALEY ALS Platform Trial; and c) NfL analysis of subjects in the open-label extension (OLE) of the HEALEY ALS Platform Trial who were initially treated with placebo during the placebo-controlled portion of the trial and then received CNM-Au8 during the OLE," said Rob Etherington, President and CEO of Clene. "The Company anticipates completing these data analyses shortly which could support the filing of an NDA using the accelerated approval pathway."

**Third Quarter 2025 and Recent Operating Highlights**

***CNM-Au8 for the treatment of ALS***

Clene held a second Type C meeting with the FDA to review the long-term survival benefit from CNM-Au8 30 mg treatment compared to concurrently randomized controls from another HEALEY ALS Platform Trial regimen in the third quarter. Consistent with prior interactions, the FDA remains focused on demonstrated improvements in ALS disease-specific biomarkers to support a regulatory filing under the accelerated approval path, with analyses of overall survival potentially serving as confirmatory evidence.

The FDA recommended three potential paths that could be leveraged to increase the persuasiveness of the Company's data, including analyses of other ALS disease-specific biomarkers and the effect of CNM-Au8 on NfL decline in various studies (NIH-sponsored EAP and HEALEY ALS Platform Trial.

Further, as recommended by the FDA, Clene plans to request a Type C meeting with the FDA to review its data from these analyses, which meeting is expected to occur in the first quarter of 2026. Assuming the further ALS data analyses are consistent with previous results and incorporating FDA feedback, the Company plans to submit an NDA under an accelerated approval pathway.

Clene also anticipates having the first patient dosed in its confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026.

***CNM-Au8 for the treatment of MS***

In September 2025, the Company held a Type B end-of-Phase 2 meeting with the FDA, during which Clene and the FDA reviewed results from the Phase 2 VISIONARY-MS trial and explored proposed endpoints for the planned Phase 3 study focusing on cognition improvement as an adjunct to standard-of-care MS therapies. The FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness to considering other potential primary endpoints, including cognition, to evaluate broader treatment effects.

In September 2025, Clene presented the combined Phase 2 REPAIR-MS trial results across relapsing MS and non-active progressive MS during the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). CNM-Au8 improved the brain's energy metabolism as evidenced by improvements to the NAD+/NADH ratio.

------

***CNM-Au8 for the treatment of PD***

In September 2025, Clene announced new preclinical data showing that CNM-Au8 improved key measures of cellular health in a novel dopaminergic neuron model of Parkinson's Disease (PD). This novel model for PD demonstrated CNM-Au8's ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic PD. These new data support the continued development of CNM-Au8 as a treatment for PD.

**Third Quarter 2025 Financial Results**

Clene's cash and cash equivalents totaled $7.9 million as of September 30, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its cash and cash equivalents as of September 30, 2025, together with $1.2 million raised subsequent to September 30, 2025, will be sufficient to fund its operations into the second quarter of 2026.

Research and development expenses were $3.5 million for the quarter ended September 30, 2025, compared to $4.5 million for the same period in 2024. The year-over-year decrease was primarily related to decreased personnel expenses, primarily due to cost-saving initiatives, and a reduction in manufacturing expenses due to the conclusion of various clinical programs; a decrease in stock-based compensation expenses due to the timing of award grants, vesting and forfeitures; a decrease in expenses related to MS clinical programs; a decrease in expenses for regulatory activities related to ongoing FDA discussions and NDA submission-related activities; and an increase in grant revenue, recorded as a reduction in research and development expense, due to an increase in the enrollment and study operations in the NIH-sponsored EAP; partially offset by an increase in expenses related to the Company's ongoing EAPs and planning activities for the Phase 3 RESTORE-ALS clinical trial.

General and administrative expenses were $2.2 million for the quarter ended September 30, 2025, compared to $3.4 million for the same period in 2024. The year-over-year decrease was primarily related to decreases in legal fees, public and investor relations expenses, personnel expenses, and stock-based compensation expenses.

Total other expense was $3.1 million for the quarter ended September 30, 2025, compared to total other expense of $0.2 million for the same period in 2024. The increase in other expense was primarily related to losses from the changes in fair value of common stock warrant liabilities and derivative liabilities, partially offset by decreases in interest expense.

Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter ended September 30, 2025, compared to a net loss of $8.0 million, or $1.22 per share, for the same period in 2024.

**About Clene**

Clene Inc. (Nasdaq: CLNN), along with its subsidiaries, "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8<sup>®</sup> is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8<sup>®</sup> is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit <u>www.clene.com</u> or follow us on <u>X</u> (formerly <u>Twitter</u>) and <u>LinkedIn</u>.

**About CNM-Au8<sup>®</sup>**

CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8<sup>®</sup> is a federally registered trademark of Clene Nanomedicine, Inc.

------

**Forward-Looking Statements**

<u>**Investor Contact**</u>: Kevin Gardner, LifeSci Advisors; <u>kgardner@lifesciadvisors.com</u>; 617-283-2856

------

**CLENE INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(In thousands, except share and per share amounts)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| Product revenue | $— | $65 | $65 | $173 |
| Royalty revenue | 15 | 22 | 58 | 78 |
| Total revenue | 15 | 87 | 123 | 251 |
| Operating expenses: |  |  |  |  |
| Cost of revenue |  | 18 | 20 | 52 |
| Research and development | 3513 | 4471 | 8508 | 14490 |
| General and administrative | 2150 | 3413 | 7183 | 10147 |
| Total operating expenses | 5663 | 7902 | 15711 | 24689 |
| Loss from operations | (5648) | (7815) | (15588) | (24438) |
| Other income (expense), net: |  |  |  |  |
| Interest income | 40 | 127 | 183 | 755 |
| Interest expense | (649) | (1022) | (1936) | (3548) |
| Change in fair value of common stock warrant liabilities | (1728) | 697 | 267 | 956 |
| Change in fair value of derivative liabilities | (797) |  | (89) |  |
| Change in fair value of Clene Nanomedicine contingent earn-out liability |  |  |  | 75 |
| Change in fair value of Initial Stockholders contingent earn-out liability |  |  |  | 10 |
| Research and development tax credits and unrestricted grants | 5 | 27 | 216 | 339 |
| Total other income (expense), net | (3129) | (171) | (1359) | (1413) |
| Net loss before income taxes | (8777) | (7986) | (16947) | (25851) |
| Income tax expense |  |  |  |  |
| Net loss | $(8777) | $(7986) | $(16947) | $(25851) |
| Other comprehensive income: |  |  |  |  |
| Unrealized loss on available-for-sale securities | $— | $1 | $— | $(1) |
| Foreign currency translation adjustments | 1 | 52 | 79 | 25 |
| Total other comprehensive income | 1 | 53 | 79 | 24 |
| Comprehensive loss | $(8776) | $(7933) | $(16868) | $(25827) |
| Net loss per share – basic and diluted | $(0.85) | $(1.22) | $(1.77) | $(4.00) |
| Weighted average common shares used to compute basic and diluted net loss per share | 10284674 | 6557839 | 9549661 | 6467771 |

---

------

**CLENE INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands, except share and per share amounts)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $7925 | $12155 |
| Accounts receivable |  | 64 |
| Inventory | 61 | 68 |
| Prepaid expenses and other current assets | 4687 | 3870 |
| Total current assets | 12673 | 16157 |
| Restricted cash | 58 | 58 |
| Operating lease right-of-use assets | 3225 | 3643 |
| Property and equipment, net | 6355 | 7479 |
| TOTAL ASSETS | $22311 | $27337 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $1369 | $1240 |
| Accrued liabilities | 4894 | 7766 |
| Operating lease obligations, current portion | 783 | 926 |
| Notes payable, current portion | 690 | 359 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convertible notes payable, current portion | 570 |  |
| Total current liabilities | 8306 | 10291 |
| Operating lease obligations, net of current portion | 3484 | 4132 |
| Notes payable, net of current portion | 4567 | 4610 |
| Convertible notes payable | 11218 | 10816 |
| &nbsp;&nbsp;&nbsp; Common stock warrant liabilities | 4274 | 4541 |
| Derivative liabilities | 2819 | 1804 |
| TOTAL LIABILITIES | 34668 | 36194 |
| Commitments and contingencies |  |  |
| Stockholders' deficit: |  |  |
| Common stock, $0.0001 par value: 600,000,000 shares authorized; 10,219,946 and 8,089,565 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 1 | 1 |
| Additional paid-in capital | 286562 | 273194 |
| Accumulated deficit | (299070) | (282123) |
| Accumulated other comprehensive income | 150 | 71 |
| TOTAL STOCKHOLDERS' DEFICIT | (12357) | (8857) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $22311 | $27337 |

---